Overview

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus

Status:
Completed

Trial end date:
2006-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to identify the safest dose of very low dose glucagon to prevent hypoglycemia in patients with Type I diabetes who use insulin pumps and to measure the the amount of glucagon in the blood and see how the body responds to the glucagon.

Phase:

Phase 1

Details

Lead Sponsor:

DiObex

Treatments:

Glucagon
Glucagon-Like Peptide 1